Core Viewpoint - Evercore's recent earnings report shows strong performance with adjusted earnings per share surpassing estimates, driven by revenue growth in key segments, although rising expenses present a challenge [2][3][5]. Financial Performance - Adjusted earnings per share for Q3 2024 were $2.04, exceeding the Zacks Consensus Estimate of $1.95 and up from $1.30 in the prior year [2]. - Total revenues reached $738.4 million, beating the consensus estimate of $695.4 million, and reflecting a year-over-year increase of 28.6% [4]. - Adjusted net revenues were $739.5 million, up 28.4% year over year, while total expenses rose 24.1% to $612.2 million [5]. Segment Performance - Investment Banking & Equities segment saw net revenues increase by 29% year over year to $712.8 million, with operating income surging 59% to $116.4 million [8]. - Investment Management segment reported net revenues of $21.4 million, a 22% increase from the prior year, with operating income up 55.1% to $5.6 million [8]. Asset Management - Assets Under Management (AUM) stood at $13.9 billion as of September 30, 2024, marking a 23.2% increase year over year [9]. Balance Sheet - As of September 30, 2024, cash and cash equivalents were $533.1 million, with investment securities and certificates of deposit totaling $1.3 billion. Current assets exceeded current liabilities by $1.6 billion [10]. Capital Distribution - In the reported quarter, Evercore repurchased 0.4 million shares at an average price of $236.91 [11]. Market Outlook - Estimates for Evercore have trended downward recently, with a consensus estimate shift of -5.58% [12][13]. The stock currently holds a Zacks Rank 3 (Hold), indicating expectations for an in-line return in the coming months [15]. Industry Comparison - Evercore operates within the Zacks Financial - Investment Bank industry, where competitor Goldman Sachs reported revenues of $12.7 billion, a year-over-year increase of 7.5% [16].

WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will pa ...

FRANKLIN LAKES, N.J., Nov. 19, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 10:50 am Eastern Time.The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.About BDBD is one of the ...

SAN DIEGO, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Evercore 7th Annual HealthCONx Conference. Details are as follows: Event: Evercore 7th Annual HealthCONx Co ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q _____________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-32975 ____________________________________________ ...

Evercore Inc.'s (EVR) third-quarter 2024 adjusted earnings per share of $2.04 surpassed the Zacks Consensus Estimate of $1.95. Also, the bottom line compared favorably with the prior-year quarter's reported figure of $1.30. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. Results benefited from an increase in revenues generated from the Investment Management and Investment Banking & Equities segments. Further, an improvement in assets under management (AUM) balance was another posit ...

Evercore Inc. (NYSE:EVR) Q3 2024 Earnings Conference Call October 23, 2024 8:00 AM ET Company Participants Katy Haber - Managing Director, Investor Relations & ESG John Weinberg - Chairman & Chief Executive Officer Tim LaLonde - Chief Financial Officer Conference Call Participants Brendan O'Brien - Wolfe Research Ryan Kenny - Morgan Stanley James Yaro - Goldman Sachs Jim Mitchell - Seaport Global Devin Ryan - Citizens JMP Aidan Hall - KBW Mike Brown - Wells Fargo Operator Good morning and welcome to the Eve ...

For the quarter ended September 2024, Evercore (EVR) reported revenue of $739.54 million, up 28.8% over the same period last year. EPS came in at $2.04, compared to $1.30 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $695.38 million, representing a surprise of +6.35%. The company delivered an EPS surprise of +4.62%, with the consensus EPS estimate being $1.95.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...

Evercore (EVR) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.95 per share. This compares to earnings of $1.30 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 4.62%. A quarter ago, it was expected that this investment bank would post earnings of $1.66 per share when it actually produced earnings of $1.81, delivering a surprise of 9.04%.Over the last four quarters, the company ha ...

Exhibit 99.1 E V E R C O R E EVERCORE REPORTS THIRD QUARTER 2024 RESULTS; QUARTERLY DIVIDEND OF $0.80 PER SHARE Third Quarter Results Year to Date Results U.S. GAAP Adjusted U.S. GAAP Adjusted Q3 2024 Q3 2023 Q3 2024 Q3 2023 YTD 2024 YTD 2023 YTD 2024 YTD 2023 Net Revenues ($ mm) $ 734.2 $ 570.2 $ 739.5 $ 576.1 $ 2,004.3 $ 1,641.8 $ 2,022.1 $ 1,659.0 Operating Income ($ mm) $ 122.0 $ 76.8 $ 134.6 $ 82.7 $ 314.4 $ 241.4 $ 339.5 $ 261.6 Net Income Attributable to Evercore Inc. ($ mm) $ 78.4 $ 52.1 $ 90.9 $ 55 ...